Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3)
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Sponsor: Eli Lilly and Company
Terminated
Solanezumab did not meet the study's primary endpoint.
Other terminated trials from Eli Lilly and Company
This PHASE3 trial investigates Alzheimer's Disease and is currently terminated or withdrawn. Eli Lilly and Company leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Terminated PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Mar 2017 — Mar 2018 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Japan , Albany, United States , Albuquerque, United States , Amherst, United States , Atlanta, United States , Auburn, United States , Baltimore, United States , Barakaldo, Spain , Barcelona, Spain , Bath, United Kingdom and 164 more locations